Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:09:20

Daily Roundup | Capricor Craters 67% as FDA Questions...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/28

Capricor fell roughly 67% after FDA briefing documentsquestioned deramiocel's efficacy days before its advisory committee — and the company's rebuttal is a fight over which statistical analysis plan governs. Webreak down what that means for cell therapy in Duchenne muscular dystrophy, argenx's $2.2 billion all-cash acquisition of Forte Biosciences for the anti-CD122 antibody FB102 in vitiligo and celiac disease, and the abrupt CEO exit at Legend Biotech as competitive pressure builds

en-us

00:13:24

Week in Review | Amgen Refuses to Pull Tavneos: FDA...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/26

Amgen told the FDA no — a blinded Duke re-analysis of ADVOCATE met noninferiority at 68.1% versus 67.1% but lost superiority, and the deadline is July 29. We unpack the avacopan withdrawal fight, the ChemoCentryx acquisition that bought it, and the EMA committee already moving against it. Plus Elevar's complete response letter for rivoceranib and camrelizumab in first-line liver cancer over a manufacturing inspection, Summit's ivonescimab survival update ahead of its November decision, Sun Pharma's

en-us

00:10:48

Daily Roundup | Novo Seeks Injunction on Lilly...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/25

Novo Nordisk is asking a court to shut down Eli Lilly'scomparative obesity ads — an injunction bid that could reset the rules for GLP-1 promotion industry-wide. Also: Sanofi ends amlitelimab development in atopic dermatitis, Ipsen's Bylvay fails the Phase 3 BOLD trial in biliary atresia, CHMP recommends NewAmsterdam Pharma and Menarini's obicetrapib and its ezetimibe combination in Europe, the FDA's peptide advisory panel splits itsvotes, Amgen fights to keep Tavneos on the market,

en-us

00:13:06

Daily Roundup | J&J Bispecific Combo Cuts Myeloma...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/24

J&J's Tecvayli–Talvey combo cut the risk of myeloma progression or death by 89% in earlier-line disease. Plus an FDA panel endorses wellness peptides including BPC-157, AstraZeneca's camizestran clears Europe in breast cancer, Repligen buys BioLife for $1.5B, BeOne's $300M reshoring push amid Trump's 200% generic tariff threat, Scribe's $129M gene-editing IPO, and Ipsen's Bylvay biliary atresia readout ahead. Visit us at thepharmacloseout.com.

en-us

00:13:34

Daily Roundup | GSK Wins First Lung Cancer Approval —...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/23

GSK's Jideytro cleared the FDA two months early — a week after the $10.6B Nuvalent deal closed — for GSK's first lung cancer approval. Plus Arrowhead's plozasiran (Redemplo) posts best-case triglyceride and pancreatitis data against Ionis's Tryngolza, Summit's ivonescimab two-year NSCLC survival ahead of its November decision, Celldex's Phase 2 failure in prurigo nodularis, Sanofi's FDA untitled letter over Beyfortus and Pfizer's RSV vaccine, and Trump's 200%

en-us

00:13:21

Daily Roundup | Novo Sues Lilly Over GLP-1 Ads: The...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/22

Novo Nordisk sued Eli Lilly in federal court over "deceptive" ads comparing high-dose Zepbound and Mounjaro to lower-dose Wegovy and Ozempic. Also: Gilead and Merck back the first weekly oral HIV pill (islatravir/lenacapavir) with 48-week Phase 3 data, Novartis beats Q2 on Kisqali and Pluvicto as pelacarsen looms, Agios scraps sickle cell drug tebapivat, Dimension closes an $800M AI-biotech fund, Bristol Myers builds an NVIDIA AI supercomputer, and Amgen settles a $74M investor suit. Visit

en-us

00:09:19

Daily Roundup | Tempus AI Buys Personalis for $1.5B...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/21

Tempus AI is buying Personalis for $1.5 billion, betting on cancer monitoring before reimbursement catches up. Plus Samsung Biologics' $1.8B all-cash bid for Swiss peptide maker PolyPeptide and its GLP-1 push, Legend Biotech's record Carvykti sales against a falling stock, Jennifer Doudna's Scribe Therapeutics CRISPR IPO, GSK shelving a $2B cough drug, Bristol Myers Squibb's Nvidia AI supercomputer, Takeda's dengue vaccine nod in India, and Novartis Fabhalta in IgA nephropathy. Visit us at

en-us

00:15:29

Week in Review | GSK Kills Camlipixant: The P2X3...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/19

GSK wrote off most of a $2 billion bet as camlipixantbecomes the third P2X3 antagonist to fail in chronic cough. Plus Lilly's $2.8B AtaiBeckley deal and July's IPO wave, Novartis Fabhalta's full approval in IgAN, Celcuity's Revtorpyk, Merck's oral PCSK9 pill and sac-TMT lung-cancerdata, the Jasper–Kira merger, and the Sanofi Sarclisa FDA decision ahead. Visit us at thepharmacloseout.com.

en-us

00:13:15

Daily Roundup | GSK Kills Camlipixant: The $2B Bellus...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/18

GSK shelved camlipixant after mixed Phase 3 data — the third P2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabhalta's full FDA approval in IgA nephropathy, Lilly's $2.8B AtaiBeckley psychedelics buyout, a Merck ADC lung cancer readout, and a Pfizer downgrade.Visit us at thepharmacloseout.com.

en-us

00:10:14

Daily Roundup | Merck's Sac-TMT Beats Chemo in Lung...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/16

Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Moderna over mRNA patents, Bora and Insilico Medicine ink a $2.5B AI alliance, the FDA resumes publishing complete response letters, Q32 Bio surges on alopecia areata data, and Veradermics posts a Phase 2 win in female pattern hair loss.Visit us at thepharmacloseout.com.

en-us

00:10:11

Daily Roundup | Celcuity Revtorpyk Approved: The...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/15

Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diranersen tau data at AAIC, the NextCure–Avere oral IL-23 merger, and Roche scrapping two Ionis Huntington's programs.Visit us at thepharmacloseout.com.

en-us

00:09:56

Daily Roundup | GSK to File Jemperli in Rectal Cancer...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/14

GSK will file Jemperli with the FDA for dMMR rectal cancer after a Phase 2 win, extending its PD-1 franchise into curative-intent oncology. Plus Q32 Bio's bempikibart hits its alopecia areata goal, the FDA finalizes psychedelics guidance ahead of a Compass Pathways COMP360 decision, LEQEMBI clears a subcutaneous at-home dose for Eisai and Biogen, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, and Biogen's tau drug diranersen takes the spotlight at AAIC.Visit us at

en-us

00:18:36

Week in Review | AstraZeneca's Wainua Stumbles: The...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/13

AstraZeneca's Wainua missed in cardiomyopathy — one of three clinical setbacks in five days even as pharma dealmaking stayed red-hot with Vertex's ~$10B Crinetics buy and GSK's biggest oncology bet in a decade. We break down what the Wainua miss means for the ATTR cardiomyopathy race, Bausch + Lomb's BL1107 glaucoma flop, the third Hengrui/Elevar liver-cancer rejection, Corcept's misread insider sale and late-2026 Cushing's catalyst for relacorilant, plus the week ahead: Q32 Bio's bempikibart in

en-us

00:09:19

Daily Roundup | GSK Ends Alector Neuroscience Bet:...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/11

GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasing rejection letters with fourteen new CRLs, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, Sanofi's subcutaneous Sarclisa wins approval, Pfizer/Astellas and Merck expand Padcev-Keytruda in muscle-invasive bladder cancer, Vera Therapeutics scores an IgA nephropathy nod against Otsuka, AstraZeneca and Ionis miss a Phase 3 heart

en-us

00:13:16

Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/10

AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform failure and what it means for Alnylam's Amvuttra and BridgeBio's Attruby, plus Roche scrapping tominersen in Huntington's, GSK exiting its Alector pact, Ipsen's Dysport dual Phase 3 migraine wins, Vera Therapeutics' IgA nephropathy approval versus Otsuka, NICE rejecting Amgen's Lumakras, and Sino Biopharm's China deals with AstraZeneca and GSK.Visit us

en-us

00:10:31

Daily Roundup | FDA Halts Drug Rejection Letters —...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/09

The FDA quietly paused publishing complete response letters after a citizen petition — reversing the Makary-era transparency push and closing a live window into rival drug failures. Plus: Sino Biopharmaceutical's dual respiratory deals with AstraZeneca ($200M upfront, TQC3721 in COPD) and GSK (Trelegy and Anoro Ellipta China rights), Vera Therapeutics' Trutakna approval in IgA nephropathy, Bristol Myers' Krazati confirmatory failure in colorectal cancer, Kailera's oral GLP-1 Phase 3 obesity data,

en-us

00:14:08

Daily Roundup | Vera's TRUTAKNA Wins FDA Nod: The...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/08

Vera Therapeutics wins FDA accelerated approval for TRUTAKNA (atacicept) in IgA nephropathy on a 42% placebo-adjusted proteinuria cut — setting up a head-to-head with Otsuka's VOYXACT. Plus Oberland Capital's up-to-$400M royalty deal for MeiraGTx eye gene therapies, Novartis cuts 322 New Jersey jobs, Bristol Myers' Krazati confirmatory failure in colorectal cancer, Roche's divarasib KRAS win, and Teva's early repigmentation data.Visit us at thepharmacloseout.com.

en-us

00:10:23

Daily Roundup | Vertex Buys Crinetics for $10B in...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/07

Vertex pays $10B cash for Crinetics Pharmaceuticals — its largest deal ever — betting on acromegaly drug Palsonify and Phase 3 CAH candidate atumelnant. Also: Novartis acquires ADC platform Myricx Bio for up to $1.5B; HSBC downgrades Pfizer to Hold after sigvotatug vedotin Phase 3 miss; BMS Krazati confirmatory study fails in CRC as Roche divarasib wins KRAS Phase 3; FDA closes H1 2026 with 23 novel approvals; Casgevy label expands to ages 2+; Roche licenses breast cancer asset from Astex.Visit us

en-us

00:09:31

Enbrel Price Cap Blocked: One Ruling That Could...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/04

Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSIVA rally hits 70% ahead of August 5 FDA decision. AstraZeneca-CSPC $1.7B kidney deal; Celea raises $180M for IPF; Orca Bio prices Tregzi at $428K.Visit us at www.thepharmcloseout.compharma, biotech, FDA, clinical trials, drug approvals, Enbrel, Amgen, drug pricing, Casgevy, CRISPR

en-us

00:10:20

Roche Divarasib Beats Both KRAS G12C Rivals in Phase...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/04

Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M raise and cleared obefazimod cancer concerns; Ipsen acquires Memo Therapeutics; BridgeBio secures $1B; Scribe Therapeutics files for IPO; FDA CBER gene therapy leadership transition.Visit us at www.thepharmacloseout.comRoche's divarasib beats both KRAS G12C rivals on PFS and OS in

en-us

171 results

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media